Vir Biotechnology (VIR) Retained Earnings (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Retained Earnings data on file, last reported at -$1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings fell 50.27% year-over-year to -$1.3 billion; the trailing twelve-month figure through Mar 2026 stood at -$1.3 billion (down 50.27% YoY), and the FY2025 full-year result was -$1.2 billion, down 69659.52% from the prior year.
• Retained Earnings retreated to -$1.3 billion in Q1 2026, from -$1.2 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $1.9 billion in Q1 2024 to a low of -$1.3 billion in Q1 2026.
• A 5-year average of $110.0 million and a median of -$3.2 million in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings jumped 57659.46% in 2024 and slumped 69659.52% in 2025, its largest moves.
• Tracing VIR's Retained Earnings over 5 years: stood at $1.7 billion in 2022, then rose by 6.96% to $1.8 billion in 2023, then slumped by 100.09% to -$1.7 million in 2024, then tumbled by 69659.52% to -$1.2 billion in 2025, then slipped by 10.49% to -$1.3 billion in 2026.
• Business Quant data shows VIR's Retained Earnings at -$1.3 billion in Q1 2026, -$1.2 billion in Q4 2025, and -$1.9 million in Q3 2025.